Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial)
Wang, J., Cheng, Y., Wu, Y-L., An, T., Gao, H., Wang, K., Zhou, Q., Hu, Y., Song, Y., Ding, C., Ye, X., Peng, F., Liang, L., Hu, Y., Huang, C., Zhou, C., Shi, Y-K., Zhang, L., Gu, Y.Volume:
27
Langue:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw383.88
Date:
October, 2016
Fichier:
PDF, 34 KB
english, 2016
File converter
Plus de résultats de recherche
More benefits 
